Overreport on the MCMI-III: concurrent validation with the MMPI-2 using a psychiatric inpatient sample

C Don Morgan1, Mike R Schoenberg, Darwin Dorr

  • 1Department of Psychiatry, University of Kansas School of Medicine, Wichita 67214-3199, USA.

Insights

The Millon Clinical Multiaxial Inventory-III (MCMI-III) shows high tolerance for symptom overreporting in psychiatric inpatients. Clinicians should be aware of this limitation when interpreting MCMI-III results alone.

Area of Science:

  • Psychological assessment
  • Clinical psychology
  • Psychopathology

Background:

  • The Millon Clinical Multiaxial Inventory-III (MCMI-III) is frequently used in inpatient psychiatric settings.
  • Patients in these settings may exaggerate symptoms, but the impact on MCMI-III validity indices is not well understood.

Purpose of the Study:

  • To investigate how symptom overreporting affects the validity indices of the MCMI-III.
  • To compare the MCMI-III Disclosure Index with validity scales of the MMPI-2.

Main Methods:

  • 191 psychiatric inpatients were studied.
  • MCMI-III modifier indices (Disclosure, Desirability, Debasement) were compared with MMPI-2 validity measures (L, F, Fb, F(p), K, F-K).
  • The MCMI-III Disclosure Index was compared against MMPI-2 validity scale cutoffs.

Main Results:

  • MCMI-III indices generally performed as expected but demonstrated a high tolerance for overreporting.
  • The MCMI-III Disclosure Index remained valid even when MMPI-2 F scale scores approached T=120.
  • The Disclosure Index met or exceeded recommended cutoffs on most MMPI-2 validity scales, excluding F-K.

Conclusions:

  • Clinicians should exercise caution when relying solely on the MCMI-III due to its significant tolerance for symptom overreporting.
  • Awareness of this limitation is crucial for accurate interpretation of MCMI-III results in clinical practice.

Related Concept Videos